Anti-TNF drugs may be associated with various adverse reactions including cutaneous ones. We describe the case of a 45-year-old woman affected by undifferentiated spondyloarthritis who presented a localized psoriasiformis dermatitis during treatment with adalimumab, without any medical history of psoriasis.
A 45-year-old woman affected by undifferentiated spondyloarthritis was sent to us for the presence on the inner thighs of erythematous papular infiltrated skin lesions coalescing in spots with severe itching and mild scaling. The patient had no personal or family history of psoriasis and stated that she had been initially treated with etanercept for undifferentiated spondyloarthritis but the therapy had been discontinued after two months because of an elevation of serum transaminases. She was consequently switched to treatment with adalimumab 40 mg (administered once every 15 days subcutaneously) and after four months of treatment, she noted the onset of cutaneous manifestations. We carried out a cutaneous biopsy on one of the lesions and a histologic examination was characterized by epidermal acanthosys, papillomatosis with lack of granular layer and parakeratosis; there was also a perivasal chronic lympho-monocytic inflammation with no eosinophils in the superficial dermis and partially vacuolated epidermal basal cells. These histologicfeatureswere compatiblewith the diagnosis ofpsoriasiformis dermatitis. We also carried out total and specific serum IgE for inhalatory allergens" all resulting negative. As the patient stated she was applying a moisturizer containing Balsam of Peru, we performed a patch test with SIDAPA standard series to exclude an allergic contact dermatitis to this allergen as we have described in another study (l) . Because of the persistence of cutaneous lesions and symptoms, in agreement with the rheumatologist, we decided to discontinue treatment with adalimumab, and a gradual improvement of the cutaneous lesions was observed, leading us to deduce that such skin manifestation was a drug-related cutaneous reaction.
Anti-TNFa drugs are currently and successfully used in the treatment of several autoimmune conditions. Tumor necrosis factor-a (TNFa) is a proinflammatory cytokine produced by a variety of cells including keratinocytes, Langerhans cells, and TNFa. is believed to play a critical role in the pathogenesis of inflammatory and autoimmune conditions such as rheumatoid arthritis, Crohn's disease and psoriasis (4, 5) .
Thus, TNFa. inhibitors (anti-TNFa. biologic drugs) have become important agents in the treatment of such diseases. Adalimumab is the first fully human monoclonal immunoglobulin directed against TNFa., which binds with high affinity and specificity to membrane and soluble TNFa.., leading to the blockade ofTNFa. activity.
However, as these drugs have gained more widespread use in the treatment of these conditions, along with the increased risk of new or latent infections such as occult hepatitis B virus and tubercolosis infections , the number and variety of cutaneous reactions has also increased, such as lichenoid, eczematous, erythema multiform-like, lupus erythematosus-like, granulomatous, vasculitic, and pseudolymphomatous lesions (6) (7) (8) . In addition to the paradoxical worsening of skin lesions in some patients with pre-existing psoriasis, clinical lesions identical to psoriasis or psoriasiform exanthemata have been reported in patients with no personal or family history of psoriasis (9) (10) (11) .
Psoriasiform reactions are the most common anti-TNFa.-induced skin manifestations, usually present in patients with personal or family history of psoriasis and have the clinical aspects of diffuse psoriasis vulgaris or palmoplantar pustolar psoriasis (12) The pathogenesis of anti-TNFa.-induced psoriasis is poorly understood but it appears that IFN-a. and plasmacytoid dendritic cells may be involved.
IFN-a. plays a key role in the early stages of psoriasis and its production by plasmacytoid dendritic cells is normally down-regulated by TNF. This is a possible operant mechanism in patients with untoward reactions to these molecules because TNFa. is known to inhibit plasmacytoid dendritic cell maturation from hematopoietic precursors (4, 13) .
Blockage ofTNF by anti-TNF drugs may lead to uncontrolled production ofIFN-a. and may cause the onset and or worsening of psoriatic lesions.
The case here reported describes the onset of a psoriasiformis localized dermatitis in a patient without personal history of psoriasis who was treated with adalimumab. We suggest that TNFa. antagonists can be associated not only to a new onset or worsening of psoriatic lesions but also to milder and localized psoriasiform cutaneous reactions.
The one we describe, may be considered a form of drug-induced reaction as the lesions significantly improved after discontinuation of the therapy.
